U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07644650) titled 'Phase 1 Study of MST-168 in Participants With Advanced Solid Malignant Tumors' on May 31.
Brief Summary: A Phase 1, multiregional, open-label study of MST-168 in participants with target-driven advanced solid tumors.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic effects, and preliminary efficacy of MST-168 in participants with target-driven advanced solid tumors. MST-168 is an investigational ADC.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Neoplams
Intervention:
BIOLOGICAL: MST-168
MST-168 is a proprietary antibody-drug conjugat...